Lenalidomide Grindeks (Lenalidomide)

Lenalidomide binds to the cereblon protein within the CRL4‑E3 ubiquitin ligase complex, redirecting the complex to degrade transcription factors Ikaros and Aiolos. This action enhances immune cell activity, inhibits new blood‑vessel formation, and directly suppresses the growth of malignant plasma cells and dysplastic blood‑forming cells, thereby exerting its anti‑cancer effects.

The specific dose of Lenalidomide Grindeks is determined by the treating physician based on the patient’s diagnosis, disease stage, renal function, and prior therapies. Prescribers follow approved labeling and clinical guidelines to select an appropriate regimen, and patients should follow the exact dosing instructions provided by their healthcare professional.

Lenalidomide is classified as teratogenic and is contraindicated in pregnancy. Women of child‑bearing potential must use effective contraception before, during, and after treatment. Safety during breastfeeding has not been established, and breastfeeding is generally discouraged while on therapy to avoid potential exposure to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Lenalidomide belongs to the immunomodulatory drug class and is often used in combination with proteasome inhibitors or steroids. Compared with older agents such as thalidomide, lenalidomide generally offers a more favorable side‑effect profile, especially regarding peripheral neuropathy, while maintaining strong anti‑myeloma activity. Choice of therapy depends on individual patient factors and treatment history.

Lenalidomide Grindeks should be stored at temperatures below 25 °C (77 °F). Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains tightly closed until use to maintain stability.

Lenalidomide Grindeks is taken orally, usually once daily, with or without food as directed by the prescribing physician. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risks include severe neutropenia and thrombocytopenia, which can lead to life‑threatening infections or bleeding, and an increased chance of venous thromboembolism. Additionally, lenalidomide carries a teratogenic risk and may be associated with secondary primary malignancies. Patients should be monitored closely for these events throughout treatment.

Lenalidomide Grindeks should not be used by individuals who are pregnant, those who cannot adhere to strict contraception, patients with known hypersensitivity to lenalidomide or its excipients, and patients with severe renal impairment without appropriate dose adjustment. Clinicians must evaluate each patient’s medical history before initiating therapy.